Last reviewed · How we verify
NCT04185935
Molecular Genetics Studies of Cancer Patients and Their Relatives
Recruiting now
Last updated 25 June 2025
What this trial tests
trial testing Biospecimen Collection in Malignant Neoplasm in 999,999 participants. Currently enrolling.
Timeline
18 April 1997
Primary endpoint
18 August 2033
18 August 2033
18 August 2033
Quick facts
| Lead sponsor | City of Hope Medical Center |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 999,999 |
| Start date | 18 April 1997 |
| Primary completion | 18 August 2033 |
| Estimated completion | 18 August 2033 |
| Sites | 42 locations across Colombia, Peru, Mexico, Puerto Rico, United States |
Drugs / interventions tested
- Biospecimen Collection — full drug profile →
- Questionnaire Administration
Conditions studied
- Malignant Neoplasm — all drugs for Malignant Neoplasm →
Sponsor
City of Hope Medical Center
Who can join
Eligibility, any sex, with Malignant Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial studies the genetic and behavioral factors that may contribute to the development of specific cancers and how these factors may affect the outcome of the disease in patients with a history of cancer and their relatives.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Genetic epidemiology of BRCA1- and BRCA2-associated cancer across Latin America.
Herzog JS, Chavarri-Guerra Y, Castillo D, Abugattas J, et al · · 2021 · cited 26× · PMID 34413315 · DOI 10.1038/s41523-021-00317-6 -
Germline mutations and age at onset of lung adenocarcinoma.
Reckamp KL, Behrendt CE, Slavin TP, Gray SW, et al · · 2021 · cited 23× · PMID 33858029 · DOI 10.1002/cncr.33573 -
Clonal Hematopoiesis and Mosaicism Revealed by a Multi-Tissue Analysis of Constitutional TP53 Status.
Castillo D, Yuan TA, Nehoray B, Cervantes A, et al · · 2022 · cited 7× · PMID 35654360 · DOI 10.1158/1055-9965.epi-21-1296 -
A Novel, Likely Pathogenic <i>MAX</i> Germline Variant in a Patient With Unilateral Pheochromocytoma.
Lam-Chung CE, Rodríguez LL, Vázquez JA, Chávarri-Guerra Y, et al · · 2021 · cited 3× · PMID 34169220 · DOI 10.1210/jendso/bvab085 -
Uptake of Risk-Reducing Surgeries in an International Real-World Cohort of Hispanic Women.
Chavarri-Guerra Y, Ferrigno-Guajardo A, Villarreal-Garza C, Martinez-Cannon BA, et al · · 2024 · PMID 39481075 · DOI 10.1200/go.24.00097
Verify or expand the search:
- PubMed search for NCT04185935
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Biospecimen Collection
Trials testing the same drug.
- NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
- NCT07441681 — Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive · Phase 3 · not yet recruiting
- NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
- NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
- NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
Other recruiting trials for Malignant Neoplasm
Currently open trials in the same condition.
- NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
- NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
- NCT07252739 — KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) · Phase 2 · recruiting
- NCT07247110 — A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001) · Phase 1 · recruiting
- NCT07131007 — Construction and Evaluation of Tumor Immunotherapy and Organ Damage Early Warning System Based on Multi-omics · recruiting
Other City of Hope Medical Center trials
Trials by the same sponsor.
- NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
- NCT07218692 — RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy · Phase 2 · not yet recruiting
- NCT07363408 — Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment · Phase 1 · not yet recruiting
- NCT07226102 — Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic o · NA · withdrawn
- NCT07225855 — Geriatric Assessment and Management for Older Adults Undergoing Chemotherapy and Radiation Therapy for Head and Neck Can · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT04185935 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by City of Hope Medical Center
- Last refreshed: 25 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04185935.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing